Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252231 | 0.83 | ERN1 (0.44) | ERN1DAOMEN1ALDH1A1KMT2A | |
| SCHEMBL488952 | 0.82 | ALDH1A1 (0.42) | ERN1DAOMEN1ALDH1A1KMT2A | |
| SCHEMBL15766289 | 0.82 | ERN1 (0.47) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL1955946 | 0.78 | ERN1 (0.44) | ERN1KDM4EPTGS2RAB9ACYP3A4 | |
| SCHEMBL27188680 | 0.78 | ERN1 (0.52) | ERN1KDM4EPTGS2RAB9ACYP3A4 | |
| SCHEMBL1359343 | 0.78 | ALDH1A1 (0.50) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL677934 | 0.78 | CYP3A4 (0.52) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL30884654 | 0.78 | ERN1 (0.52) | ERN1KDM4EPTGS2RAB9ACYP3A4 | |
| SCHEMBL17841523 | 0.75 | ERN1 (0.44) | ERN1KDM4EPTGS2RAB9A | |
| SCHEMBL275539 | 0.75 | ALDH1A1 (0.41) | ERN1MEN1ALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606571-B2 | Macrocyclic compounds and uses thereof | Turning Point Therapeutics, Inc. (US) | 2026-04-21 | — | — | US | disclosed |
| US-RE50634-E1 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12404281-B2 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240391935-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Turning Point Therapeutics, Inc. | 2024-11-28 | — | — | US | disclosed |
| EP-3658148-B1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | TURNING POINT THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3658148-B1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | TURNING POINT THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11981684-B2 | Macrocyclic compounds and uses thereof | Turning Point Therapeutics, Inc. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240140964-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4338739-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3636649-B1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals ,LLC | 2014-03-27 | — | — | US | disclosed |
| EP-2710003-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2569314-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-03-20 | — | — | EP | disclosed |
| CN-102971316-A | Fused bicyclic kinase inhibitors | OSI PHARMACEUTICALS LLC | 2013-03-13 | — | — | CN | disclosed |
| WO-2012158658-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158658-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2011143645-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | ERN1 570/4885DAO 2387/4885MEN1 519/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | ERN1 570/4885DAO 2387/4885MEN1 519/4885 |
| US-12404281-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | ERN1 700/4885DAO 4155/4885MEN1 2490/4885 |
| US-12606571-B2 | Macrocyclic compounds and uses thereof | CSF1R, CSF3R, FLT3 | ERN1 2924/4885DAO 3447/4885MEN1 375/4885 |
| US-20240140964-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | ERN1 700/4885DAO 4155/4885MEN1 2490/4885 |
| US-20240391935-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | CSF3R, CSF1R, FLT3 | ERN1 4151/4885DAO 4092/4885MEN1 318/4885 |
| US-11981684-B2 | Macrocyclic compounds and uses thereof | CSF3R, CSF1R, FLT3 | ERN1 4151/4885DAO 4092/4885MEN1 318/4885 |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | IGF1R, MET, RET | ERN1 996/4885DAO 2973/4885MEN1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.